ChunLab Inc

ChunLab Inc

311690 · KQ · Healthcare / Biotechnology

3,550.00KRW+50.00 (+1.43%)

Price History

Full chart

Market Stats

Previous Close3,500.00
Open3,490.00
Day Range3,310.00 – 3,590.00
52-Week Range3,060.00 – 10,200.00
Volume10.72K
Market Cap48.41B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.54
50-Day Avg3,782.40
200-Day Avg6,414.30

About

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics analysis portal for microbial research; EzBioCloud Pro, a next-generation analysis platform for infection diagnosis and microbial bioinformatics analysis; Gut Inside, a microbiome testing service; and TrueBac ID, a cloud-based service platform that can identify various bacterial species based on genomic data. The company was formerly known as ChunLab, Inc. and changed its name to CJ Bioscience, Inc. in December 2021. CJ Bioscience, Inc. was founded in 2009 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Eun-ji Kim
  • Employees122
  • HeadquartersGrand Central, Seoul, South Korea, 04527, Korea
  • Websitehttps://www.cjbioscience.com

Leadership

  • Ms. Eun-ji KimHead of Strategic Planning · b. 1979

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.67B3.92B4.78B5.31B4.36B4.07B5.58B3.47B3.69B
Growth (%)-+6.85%+21.90%+11.05%-17.86%-6.61%+36.82%-37.82%+6.52%
Cost of Revenue1.79B1.73B2.11B2.90B2.71B2.67B3.73B3.10B2.99B
Gross Profit1.88B2.20B2.67B2.41B1.65B1.41B1.84B365.37M698.91M
Gross Margin51.21%56.01%55.89%45.46%37.89%34.49%33.06%10.54%18.93%
Operating Expense4.50B5.60B7.19B10.93B13.90B34.64B33.82B34.61B25.48B
Operating Income-2.62B-3.41B-4.52B-8.51B-12.24B-33.23B-31.98B-34.24B-24.79B
Operating Margin-71.29%-86.81%-94.47%-160.28%-280.61%-815.61%-573.64%-987.76%-671.24%
EBITDA------28.25B-16.84B-27.93B-19.45B
EBITDA Margin------693.32%-302.15%-805.68%-526.79%
Net Income-2.36B-3.13B-4.35B-8.76B-19.27B-34.91B-22.91B-32.84B-24.00B
Net Income Margin-64.34%-79.89%-90.85%-164.97%-441.72%-856.84%-410.99%-947.28%-650.10%
R&D--3.40B4.98B4.85B19.19B22.82B23.17B18.05B
R&D as % of Total Revenue--71.06%93.83%111.22%470.85%409.38%668.30%488.86%
Interest Expense0045.33M1.62B4.97B2.76B922.05M587.41M540.18M
Interest Expense % of Total Revenue0.00%0.00%0.95%30.54%113.86%67.81%16.54%16.95%14.63%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.99B12.83B33.74B73.36B116.36B91.39B91.13B99.61B72.34B
Total Liabilities1.83B2.06B2.89B38.88B28.50B41.73B19.63B21.85B18.70B
Total Equity13.16B10.78B30.85B34.48B87.85B49.66B71.50B77.76B53.64B
Cash178.81K148.59K5.33B13.26B62.06B49.32B64.10B8.31B10.34B
Total Debt--368.15M35.56B-----
Net Debt---21.83B-----

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.57B-2.03B-2.51B-7.98B-8.44B-20.99B-24.90B-27.76B-23.42B
Investing Cash Flow11.50B-160.78M-26.17B-26.51B6.45B7.16B16.70B-67.56B-
Financing Cash Flow-18.57M19.41M23.27B42.35B50.71B1.02B22.94B39.50B-
Capital Expenditure602.70M156.78M427.22M12.02B952.65M4.14B16.42B583.62M75.93M
Free Cash Flow---2.96B-26.84B-9.42B-25.86B-41.32B-28.34B-23.49B
FCF to OCF--118.09%336.46%111.60%123.20%165.93%102.10%100.32%

Earnings

Report DateDec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 28, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------
EPS Actual-252.66-416.07-597.68-513.88-462.22-779.38-1510.99-598.71-1085.21-919.36-1171.09-1315.92-1802.17-1085.58-1428.08-1052.11192.08-809.28-848.28-906.61-976.47-469.08-526.92-446.12-395.16-392.46-475.14
Surprise---------------------------
Timing----------------Pre-market----------

Key Statistics & Ratios

Market Cap48.41B
Enterprise Value15.40B
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.16
Price / Book1.16
Revenue (TTM)3.68B
Gross Profit (TTM)718.04M
EBITDA-19.15B
Profit Margin0.00%
Operating Margin-712.50%
Return on Equity-41.76%
Return on Assets-20.11%
Shares Outstanding13.07M
Shares Float4.51M
Beta0.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 7, 20237987:7004